Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference

Rhea-AI Summary

Finch Therapeutics (Nasdaq: FNCH) has announced its participation in two upcoming investor conferences. The Jefferies London Healthcare Conference will feature a corporate presentation by Chief Medical Officer Howard Franklin on November 16, 2022. The Evercore ISI HealthCONx Conference will include a fireside chat with CEO Mark Smith on December 1, 2022. Live webcasts of both presentations will be available on Finch's website, with replays accessible for 30 days. Finch is known for its innovative microbiome therapeutics and is advancing its lead candidate, CP101, for recurrent C. difficile infections.

SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery^® platform to develop a novel class of orally administered biological drugs, today announced that the company will present at the following investor conferences:

• Jefferies London Healthcare Conference
  Wednesday, November 16, 2022 at 10:55 am GMT
  Corporate presentation by Howard Franklin, MD, MBA, Chief Medical Officer

• Evercore ISI HealthCONx Conference
  Thursday, December 1, 2022 at 11:20 am ET
  Fireside chat with Mark Smith, PhD, Chief Executive Officer

Live webcasts of both events will be available under the ‘Investors & News’ section of the Finch website. Replays of the webcasts will be available on Finch’s website for approximately 30 days after each event.

About Finch Therapeutics

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is exploring strategic options to potentially advance the development of its pre-clinical candidates FIN-524 for ulcerative colitis and FIN-525 for Crohn's disease and its pre-clinical program in autism spectrum disorder. Finch routinely posts information that may be important to its investors on its website at www.finchtherapeutics.com. Finch encourages investors to consult the “Investors & News” section of its website regularly.

Human-First Discovery^® is a registered trademark of Finch Therapeutics Group, Inc.

Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com

FAQ

What is Finch Therapeutics presenting at the Jefferies London Healthcare Conference?

Finch Therapeutics will present a corporate presentation by Chief Medical Officer Howard Franklin on November 16, 2022.

When will Finch Therapeutics hold a fireside chat at the Evercore ISI HealthCONx Conference?

The fireside chat will take place on December 1, 2022, with CEO Mark Smith.

Where can I watch the live webcasts of Finch Therapeutics' conference presentations?

Live webcasts of the presentations will be available on Finch's website under the 'Investors & News' section.

What is the lead candidate of Finch Therapeutics and its purpose?

Finch's lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infections.

What designations has Finch Therapeutics received for its lead candidate?

CP101 has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration.